Abstract

Molecular and brain regional/network-wise pathophysiological changes at preclinical stages of Alzheimer's disease (AD) have primarily been found through knowledge-based studies conducted in late-stage mild cognitive impairment/dementia populations. However, such an approach may compromise the objective of identifying the earliest spatial-temporal pathophysiological processes. We investigated 261 individuals with subjective memory complaints, a condition at increased risk of AD, to test a whole-brain, non-a-priori method based on partial least squares in unraveling the association between plasma Aβ42/Aβ40 ratio and an extensive set of brain regions characterized through molecular imaging of Aβ accumulation and cortical metabolism. Significant associations were mapped onto large-scale networks, identified through an atlas and by knowledge, to elaborate on the reliability of the results. Plasma Aβ42/40 ratio was associated with Aβ-PET uptake (but not FDG-PET) in regions generally investigated in preclinical AD such as those belonging to the default mode network, but also in regions/networks normally not accounted - including the central executive and salience networks - which likely have a selective vulnerability to incipient Aβ accumulation.The present whole-brain approach is promising to investigate early pathophysiological changes of AD to fully capture the complexity of the disease, which is essential to develop timely screening, detection, diagnostic, and therapeutic interventions.

Highlights

  • Brain accumulation of amyloid-β (Aβ) aggregation species is one of the earliest pathophysiological alterations in the preclinical phase of the Alzheimer’s disease (AD) clinical-biological continuum

  • The study sample consisted of 318 participants with subjective memory complain (SMC), who were enrolled in the standardized, large-scale, observational, monocentric, French academic university-based “INveStIGation of AlzHeimer’s PredicTors in Subjective Memory Complainers” (INSIGHT-preAD) study (Dubois et al, 2018) – that is part of the Alzheimer Precision Medicine Initiative (APMI) and its established Cohort Program (APMI-CP) (Hampel et al, 2019b)

  • Our study shows that plasma Aβ42/Aβ40 ratio is negatively associated with several regional Aβ-Positron emission tomography (PET) indexes at a cross-sectional and longitudinal level in subjective memory complaints (SMC) individuals

Read more

Summary

Introduction

Brain accumulation of amyloid-β (Aβ) aggregation species is one of the earliest pathophysiological alterations in the preclinical phase of the Alzheimer’s disease (AD) clinical-biological continuum Individuals at risk for AD or any other neurodegenerative disease may have different clinicalbiological trajectories with some developing brain resilience, at the molecular and network level, while other individuals may develop multi-scale system failure and cognitive decline (ArenazaUrquijo and Vemuri, 2018; Elman et al, 2014; Perez-Nievas et al, 2013). Reliable multi-modal exploratory and integrative approaches are needed for investigating network dysfunction in AD trajectories and resilience in individuals displaying incipient molecular signatures of AD or any other neurodegenerative disease

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call